| Health / Medical Topics |
ESO-1:157-165(165V) Peptide
A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI Thesaurus)
YOU MAY ALSO LIKE
Tumor infiltrating lymphocytes (TIL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the…
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to…
A cancer vaccine consisting of an immunogenic peptide sequence from the cancer-testis antigen ESO-1, an antigen found in normal testis and various…
A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may…
The hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid…
Human ESM1 wild-type allele is located in the vicinity of 5q11.2 and is approximately 8 kb in length. This allele, which encodes…
